ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
68 677,49
0,21%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Karyopharm Therapeutics Inc (KPTI)

  7. Karyopharm Therapeutics Inc (KPTI) Actualités

KPTI

Karyopharm Therapeutics (KPTI)

Karyopharm Therapeutics Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:KPTI
DateHeureSourceTitreSymboleSociété
23/05/202422h30Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:KPTIKaryopharm Therapeutics Inc
14/05/202422h06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422h13Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202422h05PR Newswire (US)Karyopharm to Participate at the 2024 RBC Capital Markets Global Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413h30PR Newswire (US)Karyopharm Reports First Quarter 2024 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
08/05/202413h30PR Newswire (US)Karyopharm Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029NASDAQ:KPTIKaryopharm Therapeutics Inc
07/05/202422h56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
02/05/202422h30PR Newswire (US)Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
01/05/202422h05PR Newswire (US)Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:KPTIKaryopharm Therapeutics Inc
24/04/202422h01PR Newswire (US)Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingNASDAQ:KPTIKaryopharm Therapeutics Inc
06/03/202422h05PR Newswire (US)Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202413h43Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:KPTIKaryopharm Therapeutics Inc
29/02/202413h30PR Newswire (US)Karyopharm Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
22/02/202413h00PR Newswire (US)Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024NASDAQ:KPTIKaryopharm Therapeutics Inc
14/02/202416h33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:KPTIKaryopharm Therapeutics Inc
08/01/202414h30PR Newswire (US)Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 ObjectivesNASDAQ:KPTIKaryopharm Therapeutics Inc
03/01/202413h00PR Newswire (US)Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:KPTIKaryopharm Therapeutics Inc
11/12/202302h15PR Newswire (US)Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor (JAKi)-Naïve Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)NASDAQ:KPTIKaryopharm Therapeutics Inc
08/11/202322h05PR Newswire (US)Karyopharm to Participate at Upcoming Investor ConferencesNASDAQ:KPTIKaryopharm Therapeutics Inc
06/11/202313h00PR Newswire (US)Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO StudyNASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202314h20PR Newswire (US)Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)NASDAQ:KPTIKaryopharm Therapeutics Inc
02/11/202312h30PR Newswire (US)Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
30/10/202313h00PR Newswire (US)Karyopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD™ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple MyelomaNASDAQ:KPTIKaryopharm Therapeutics Inc
26/10/202313h00PR Newswire (US)Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
26/09/202313h00PR Newswire (US)Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual MeetingsNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202314h17Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:KPTIKaryopharm Therapeutics Inc
01/09/202314h00PR Newswire (US)Karyopharm Appoints Zhen Su, MD, MBA to its Board of DirectorsNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202314h59Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:KPTIKaryopharm Therapeutics Inc
02/08/202313h30PR Newswire (US)Karyopharm Reports Second Quarter 2023 Financial Results and Highlights Recent Company ProgressNASDAQ:KPTIKaryopharm Therapeutics Inc
26/07/202313h00PR Newswire (US)Karyopharm to Report Second Quarter 2023 Financial Results on August 2, 2023NASDAQ:KPTIKaryopharm Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:KPTI

Dernières Valeurs Consultées

NYSE
MCD
McDonalds
NASDAQ
NVDA
NVIDIA
USI
USTECH100
US Tech 100
EU
EN
Bouygues
EU
PX1
CAC 40
EU
CS
Axa
EU
PX4
SBF 120
EU
RNO
Renault
EU
MC
Lvmh Moet Hennessy Louis...
EU
VK
Vallourec
EU
GLE
Societe Generale
NASDAQ
MSFT
Microsoft
EU
ORA
Orange
NYSE
JPM
JP Morgan Chase
NYSE
MRK
Merck
NYSE
DIS
Walt Disney
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés